Atara Biotherapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

ATRA$8.10-1.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(In thousands)

Accumulated
Common · Additional · Other · Total
Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
For the Six Months Ended June 30, 2026 · Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit)
Balance as of January 1, 2026	7,324		$1		$1,983,361		$1		$(2,021,865)		(38,502)
Issuance of pre-funded warrants in connection with HCRx Amendment	—		—		$1,672		—		—		1,672
Issuance of common stock through ATM facilities, net of commissions and offering costs of $82	493		—		2,915		—		—		2,915
Exercise of pre-funded warrants	630		—		—		—		—		—
RSU settlements, net of shares withheld	65		—		—		—		—		—
Stock-based compensation expense	—		—		749		—		—		749
Net (loss) income	—		—		—		—		(4,145)		(4,145)
Unrealized gain (loss) on available-for-sale securities	—		—		—		(1)		—		(1)
Balance as of March 31, 2026	8,512		$1		$1,988,697		$—		$(2,026,010)		$(37,312)
Issuance of common stock through ATM facilities, net of commissions & offering cost of $145	498		—		4,758		—		—		4,758
Stock-based compensation expense		—		394		—		—		394
Exercise of pre-funded warrants	362		—		—		—			—
RSU settlements, net of shares withheld	71		—		—		—		—		—
Net (loss) income	—		—		—		—		(4,834)		(4,834)
Unrealized gain (loss) on available-for-sale securities	—		—		—		(2)		—		(2)
Balance as of June 30, 2026	9,443		$1		$1,993,849		$(2)		$(2,030,844)		$(36,996)

Accumulated
Common · Additional · Other · Total
Stock · Paid-in · Comprehensive · Accumulated · Stockholders’
For the Six Months Ended June 30, 2025 · Shares · Amount · Capital · Income (Loss) · Deficit · Equity (Deficit)
Balance as of January 1, 2025	5,859	$1	$1,957,261		$8	$(2,054,553)	$(97,283)
RSU settlements, net of shares withheld	65	—	—		—	—	—
Stock-based compensation expense	—	—	4,209		—	—	4,209
Net (loss) income	—	—	—		—	38,010	38,010
Unrealized gain (loss) on available-for-sale securities	—	—	—		(8)	—	(8)
Balance as of March 31, 2025	5,924	$1	$1,961,470		$—	$(2,016,543)	$(55,072)
Issuance of pre-funded warrants to purchase common stock through an underwritten registered direct offering, net of offering costs of $522	834	—	14,843		—	—	14,843
RSU settlements, net of shares withheld	220	—	(1)		—	—	(1)
Issuance of common stock pursuant to employee stock awards	—	—	1		—	—	1
Stock-based compensation expense	—	—	2,801		—	—	2,801
Net (loss) income	—	—	—		—	2,387	2,387
Balance as of June 30, 2025	6,978	$1	$1,979,114	$	-	$(2,014,156)	$(35,041)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.